Design Therapeutics Inc
DSGN4.020USD
+0.200+5.24%
Market hours （ET）Quotes delayed by 15 min
228.21MMarket Cap
LossP/E TTM
More Details of Design Therapeutics Inc Company
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
Ticker SymbolDSGN
Company nameDesign Therapeutics Inc
IPO dateMar 26, 2021
CEODr. Pratik Shah, Ph.D.
Number of employees54
Security typeOrdinary Share
Fiscal year-endMar 26
Address6005 Hidden Valley Road
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92011
Phone18582934900
Websitehttps://www.designtx.com/
Ticker SymbolDSGN
IPO dateMar 26, 2021
CEODr. Pratik Shah, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Christopher M. (Chris) Storgard, M.D.
Dr. Christopher M. (Chris) Storgard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Arsani H. William, M.D.
Dr. Arsani H. William, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rodney W. Lappe, Ph.D.
Dr. Rodney W. Lappe, Ph.D.
Independent Director
Independent Director
133.02K
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
129.92K
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
57.64K
--
Ms. Deepa Prasad
Ms. Deepa Prasad
Independent Director
Independent Director
20.00K
--
Dr. Heather A Berger ,Ph.D.
Dr. Heather A Berger ,Ph.D.
Independent Director
Independent Director
1.30K
--
Dr. Sean Jeffries, Ph.D.
Dr. Sean Jeffries, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ansari (Aseem Z. Ph.D.)
13.51%
SR One Capital Management, LP
11.50%
Logos Global Management LP
7.43%
Quan Venture Fund II LP
7.04%
Light Irrevocable Trust.
6.75%
Other
53.77%
Shareholders
Shareholders
Proportion
Ansari (Aseem Z. Ph.D.)
13.51%
SR One Capital Management, LP
11.50%
Logos Global Management LP
7.43%
Quan Venture Fund II LP
7.04%
Light Irrevocable Trust.
6.75%
Other
53.77%
Shareholder Types
Shareholders
Proportion
Corporation
20.55%
Venture Capital
18.93%
Hedge Fund
15.58%
Individual Investor
15.54%
Investment Advisor
13.62%
Investment Advisor/Hedge Fund
8.75%
Private Equity
3.44%
Research Firm
0.58%
Pension Fund
0.09%
Other
2.92%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
236
55.16M
97.16%
-18.43M
2025Q1
248
55.19M
97.22%
-19.02M
2024Q4
263
54.33M
95.95%
-18.64M
2024Q3
271
52.86M
93.39%
-18.89M
2024Q2
270
52.91M
93.60%
-20.44M
2024Q1
269
51.55M
91.19%
-22.56M
2023Q4
256
52.68M
94.11%
-19.20M
2023Q3
248
54.08M
96.62%
-10.45M
2023Q2
240
59.86M
106.99%
-4.32M
2023Q1
237
59.61M
106.56%
-4.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ansari (Aseem Z. Ph.D.)
7.67M
13.51%
--
--
Mar 31, 2025
SR One Capital Management, LP
6.53M
11.5%
--
--
Mar 31, 2025
Logos Global Management LP
4.22M
7.43%
--
--
Mar 31, 2025
Quan Venture Fund II LP
4.00M
7.04%
-133.00K
-3.22%
Mar 31, 2025
Light Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
Star Irrevocable Trust.
3.83M
6.75%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.20M
3.88%
-73.03K
-3.21%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.95M
3.44%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.82M
3.2%
-38.89K
-2.09%
Mar 31, 2025
Baker Bros. Advisors LP
1.74M
3.07%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Micro-Cap ETF
0.02%
Fidelity Enhanced Small Cap ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Micro-Cap ETF
Proportion0.02%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
